Nexalin Technology, Inc. (NXL) is a Medical - Devices company in the Healthcare sector, currently trading at $0.51. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Valuation: NXL trades at a trailing Price-to-Earnings (P/E) of -0.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Financials: revenue is $301,647, +13.2%/yr average growth. Net income is $8M (loss), growing at -71%/yr. Net profit margin is -2725.8% (negative). Gross margin is -543.4% (-615.9 pp trend).
Balance sheet: total debt is $0 against $4M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 4.85 (strong liquidity). Debt-to-assets is 0%. Total assets: $5M.
Analyst outlook: 1 / 1 analysts rate NXL as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
